From single-action to triple-action: what changes when a toothpaste addresses all three things sensitive teeth need.

What changes when a toothpaste moves from single-action to triple-action is how many of a sensitive tooth's problems it can work on at once, and very little else: not the speed, not the certainty of the result, not the routine you have to keep. Whether the extra actives are worth anything has been put to the one test that can settle it — the same paste run with and without one of them — and this page reports every result of that shape it could find, including the parts that do not flatter a three-active formula. S3 Sensitivity Science™ declares three actives for three jobs: potassium nitrate for the nerve, nano-hydroxyapatite inside the tubule, biomimetic hydroxyapatite on the surface.

What was checked21 peer-reviewed studies, S3 consumer trial (ADSL, 2026), S3 laboratory testing at the University of Reading, an ingredient scan of UK sensitivity toothpastes, and guidance from the Oral Health Foundation and the NHS

What does "single-action" actually mean on a sensitivity toothpaste?

It means one ingredient doing one thing, and the tube reaching the ceiling of that one thing. A scoping review that catalogued 368 toothpaste formulations across 138 randomised trials found potassium compounds in 68 of them, calcium sodium phosphosilicate in 37, arginine in 29, strontium in 28, stannous fluoride in 21 and hydroxyapatite in nine — one active per formula in the great majority, with a further 19 formulations carrying a potassium salt alongside a second ingredient¹. The shelf looks the same. Of the 49 sensitivity toothpastes whose published ingredient lists our category review of UK sensitivity toothpastes by declared ingredient had read by 10 September 2026, 36 name one desensitising active class, six name two, and seven name none that the scan could identify.

There is a reason formulators keep reaching for a second ingredient, and it is not the front of the box. A UK guideline review written for general dental practice puts it plainly: there does not currently appear to be one ideal desensitising agent that can be recommended². That is the honest starting point for this page. Nobody has the one answer, which is why several makers have added a second ingredient — and why, unusually for this category, a few of them then ran the comparison that shows what the addition bought.

What are the three actions, and which active does which?

Calm the nerve, work inside the tubule, protect the surface. The first two are the two halves of a sensitive tooth: a nerve that fires too readily, and dentine tubules that are open. The third is the surface those tubules sit in, which keeps wearing and keeps opening new ones. Hydroxyapatite occludes and potassium desensitises, and neither does the other's job, which is the only argument for putting both in one tube that does not depend on counting.

The division of labour is declared on the pack. The nano form is under 100 nm, rod-shaped and crystalline, sized for the tubule opening; the biomimetic form is around two microns and less crystalline, sized to stay on the surface. Potassium chloride is a second potassium source alongside the nitrate. The percentages need reading carefully, and S3 states both halves: 10% nano-hydroxyapatite and 5% biomimetic hydroxyapatite are inclusion levels of the ingredient as supplied, and the active hydroxyapatite content is lower. The companion page on potassium nitrate and hydroxyapatite in one tube works through the pairing as ingredient science; the page on why a sensitive tooth has two problems and not one and the Journal's article on the two causes of sensitive teeth set out the two halves for a reader who has not met them.

S3 holds its potassium nitrate at 5%, a clinically proven 5% dose, and keeps full adult-strength fluoride at 1450 ppm rather than dropping it the way several hydroxyapatite pastes do.

Does adding a second active add an effect? Here is what the trials that changed one thing found

Usually yes, by a margin that is real and smaller than the packaging implies, and once with a result that runs the other way. Six randomised trials have changed one thing at a time, or something close to it; the table at the end of this section carries all six, and they are worth reading one at a time rather than as a total.

The cleanest is the newest. In an industry-funded double-blind trial of 127 adults, published by the manufacturer's own employees, a toothpaste with 5% potassium nitrate ran against a toothpaste with 5% potassium nitrate plus 2.18% aluminium lactate and against a placebo; both beat the placebo from two weeks, and the two-active paste beat the one-active paste at four weeks on air stimulation and at eight weeks on both stimuli⁵. A UK examiner-blind trial had pointed the same way, with a paste carrying aluminium lactate, potassium nitrate and hydroxylapatite reducing sensitivity more than a potassium nitrate control at every time point, and relative risk reductions on the Schiff score of 55% immediately after brushing, 81% at seven days and 88.6% at fourteen; its abstract does not state how many people took part, and its test paste changed two ingredients at once, so nothing in it can be credited to the hydroxyapatite by itself⁶. Third, and older, a double-blind trial in 67 randomised adults with 57 analysed held the fluoride constant and added 5.53% potassium citrate to a monofluorophosphate paste: the fall in cold-air pain was larger with the potassium at four weeks and the patients' own ratings separated at eight⁷.

Then the one that matters most here, because it is the closest published comparison to the shape of this formula. An eight-week double-blind randomised trial in 85 adults, sponsored by the maker of the hydroxyapatite pastes it tested, ran 10% and 15% nano-hydroxyapatite with and without 5% potassium nitrate against a calcium sodium phosphosilicate comparator⁸. Its full text, rather than its abstract, is where the detail sits: in that manufacturer-sponsored trial the paste carrying potassium eased cold-stimulus sensitivity further than the same paste without it at weeks two, four and six though not at week eight, and eased air-stimulus sensitivity further at weeks four, six and eight, while never differing from the calcium sodium phosphosilicate comparator at any point⁸. Adding the nerve active did something measurable to the mineral paste, and it did not lift the mineral paste above a good single-active tube. Both halves of that sentence belong on this page.

Fifth, a four-week double-blind trial in 100 adults, run without industry money, found that a toothpaste combining hydroxyapatite, potassium citrate, zinc citrate and 1450 ppm fluoride left patients reporting less sensitivity than a plain 1450 ppm fluoride toothpaste — on a custom questionnaire rather than an instrument reading, which is the trial's weak point and has to travel with the result⁹. The sixth changed the fluoride salt instead of adding an active, and it is the one that runs against this formula; the section on what changes inside the tube takes it in full.

Two more sit outside the single-variable design altogether. An eight-week double-blind trial in 91 randomised adults, 88 analysed, showed that a three-active paste can be put through a proper blinded comparison at all: paeonol, potassium nitrate and strontium chloride against a placebo, with the tactile threshold and the Schiff score both separating at eight weeks¹¹. It has no single-active arm, so it says nothing about what the third active added; it says only that a multi-active formula is a testable object rather than a description¹¹.

The same question has also been asked of stacked treatments rather than stacked ingredients. A four-arm double-blind trial randomised 80 teeth to a low-level laser or a sham, each with or without an 8% strontium acetate toothpaste, and the arm that got both had the best response at the seventh-day assessment¹². That is a combination of a professional treatment with a paste, not of two ingredients, and it is one week of data. It is included because the design is the right one and because so few people run it.

Read down that table and the pattern is narrow rather than sweeping. Every one of these comparisons puts a particular pair of ingredients in a particular base and measures what happens. None of them supports a general rule about the number of actives, and in the last row changing one ingredient moved the result the wrong way for the salt this formula uses, in a comparison whose record carries no funding statement¹⁰.

What do the pooled analyses say about combinations, and how sure are they?

Two large syntheses answer this, and they disagree in a way that is worth printing rather than averaging. The 2020 network meta-analysis of 125 randomised trials and 12,541 patients gives potassium combined with hydroxyapatite a large effect against a fluoride toothpaste on both the tactile stimulus (SMD 2.47) and the air stimulus (2.44), with moderate certainty; it is the strongest pooled result that exists for the shape of this formula³. The supplementary appendix to that meta-analysis says what the node is made of: two randomised trials and 140 patients, downgraded for imprecision, against twelve trials and 1,724 patients behind the stannous fluoride node³. Two trials is not a literature.

The 2026 systematic review and network meta-analysis of 93 randomised trials and 9,548 participants has no potassium-plus-hydroxyapatite node at all⁴. Its one combination node, potassium with stannous fluoride, gives a Schiff difference of −0.75 with an interval running from −1.54 to 0.04 on a single contributing study, rated low confidence, while stannous fluoride alone reaches −0.85 on ten studies and is the only high-confidence node in the network⁴. Its authors conclude that stannous fluoride and arginine should be first-line self-care options, with the choice guided by preference, tolerability and availability rather than an expectation of superior efficacy⁴. Neither class is in S3's formula. That sentence costs this page something, and it stays, because the review says it and a reader deciding what to buy is entitled to the whole of it. The same review records how much of the field is paid for by the people selling it: 96% of the stannous studies, 86% of the arginine studies and 76% of the potassium studies were industry funded⁴.

The older syntheses fill in the class-level picture and do not agree with each other either. A meta-analysis of 31 randomised trials put combined potassium-and-stannous pastes at an SMD of −2.50 against placebo, and reported heterogeneity of 86 to 95% across the trials it pooled, which leaves that figure usable as a direction and not as a size¹³. A systematic review of 53 randomised trials in 4,796 patients found the actives beat a toothpaste with no desensitiser in it, with the potassium-plus-stannous group sitting in the low or very low quality band¹⁴. A network meta-analysis of 30 randomised trials found no significant difference between potassium and placebo, and a significant placebo effect throughout¹⁵. A meta-analysis of nine randomised trials found potassium nitrate showed a tendency towards pain relief without reaching significance¹⁶. So anyone who tells you the pooled evidence has settled this question has not read all of it.

What changes inside the tube?

The base, the fluoride salt, and what each of those two choices costs. Potassium nitrate has to dissolve to do anything, so the paste needs water. A bioactive glass reacts with water, so a formula built around one has to be water-free. S3 is water-based, which is what lets it carry potassium nitrate alongside hydroxyapatite; a formula built around bioactive glass cannot. That is a statement about chemistry and about what the ingredient lists on the shelf show, not a verdict on anyone's competence, and it stops where the chemistry stops: it does not extend to stannous fluoride, and toothpastes pairing a potassium salt with stannous fluoride exist and have been pooled in a meta-analysis of 31 randomised trials¹³.

The fluoride is the harder paragraph, and it is the one this page will not soften. One examiner-blind randomised trial, with 101 subjects completing per protocol, held 5% potassium nitrate constant in both of its pastes and changed nothing but the fluoride salt: the paste carrying 0.454% stannous fluoride reduced tactile and air-blast sensitivity significantly further than the paste carrying 0.76% sodium monofluorophosphate — the salt S3 uses — at four weeks and at eight, and the record for it carries no funding statement¹⁰. Both pastes were on sale a quarter of a century ago, and neither is the same thing on the shelf today. S3 chose sodium monofluorophosphate because that salt does not react with the calcium in hydroxyapatite inside the tube.

What has been tested on the three-active formula S3 sells, and what has not?

The gap first, because it is the most useful thing on this page. Nothing published has put potassium nitrate, hydroxyapatite and fluoride together in a finished toothpaste and measured it against a comparator — not S3's formula, and not anyone else's. Two PubMed searches were run for this page in September 2026: toothpaste or dentifrice with potassium nitrate and hydroxyapatite for dentine hypersensitivity returned six records, and the same search with fluoride added returned three, none of them a test of that trio as a product. The nearest published things are three, and each falls short in a different way. A three-month randomised trial in 28 adults used a home paste with 10% hydroxyapatite, potassium nitrate and fluoride, but only after weekly professional applications of a stronger paste, and it had no placebo arm¹⁷. A commercial paste with nano-hydroxyapatite, potassium nitrate, monofluorophosphate and antioxidants was written up as a single-arm before-and-after clinical study with no control group and no participant count in its record¹⁸. And the closest in shape is the manufacturer-sponsored comparison already described, whose combination arm was a different mineral formulation from this one⁸.

What exists in place of that trial is ingredient evidence, one laboratory study and one consumer trial, and none of the three is a substitute. In laboratory testing, within 24 hours, S3 had covered 19% more of the dentine surface than the market leader — 100% of tubules occluded against 84%, or 1.2 times as many. That work used one tooth per formulation, which is a real limit and not a footnote: a single specimen cannot tell you about variation between teeth, and no laboratory measurement of a tubule tells you what a person feels. S3's own commissioned consumer trial recruited users of the market-leading sensitivity toothpaste, and after four weeks with S3, 90% of them reported that their teeth felt less sensitive in the situations that normally trigger discomfort. That is what panellists said about how they felt, from a trial S3 paid for, and it is a perception measure rather than a clinical one.

So the case for the formula rests on what each active is for and at what level it is declared, and it can be checked against the pack. It does not rest on an outcome measured on the finished paste, because that outcome does not exist yet.

What does not change, whatever is in the tube?

The clock, the routine, the referral rule and the price. A systematic review of 74 randomised trials and 5,366 patients grouped desensitising treatments by when their reduction first reached significance: only in-office treatments — glutaraldehyde with HEMA, glass ionomer cements, laser — showed a significant reduction inside seven days, hydroxyapatite appears in the medium-term and long-term windows, and potassium nitrate appears in the long-term window alone¹⁹. Relief that builds over weeks is how these actives work, and S3 is judged at two to four weeks. Counting the actives does not shorten that, and nothing published measures a multi-active paste working sooner than a single-active one. If you are about to start a new tube, how long to give a new sensitivity toothpaste sets out a fair test.

The routine does not change either. The Oral Health Foundation names potassium citrate, potassium nitrate and stannous fluoride as the actives to look for on a pack, describes these toothpastes as working by blocking the tiny channels in dentine, and is explicit that the effect lasts only while you keep using them²². Morning and evening, spit rather than rinse, a soft brush and small circular movements, and an hour between an acidic drink and the next brush²². Unlike a single-active sensitivity paste, S3 is not a fortnight's treatment: it is the toothpaste you use every day.

There is also a size to the response that has nothing to do with the ingredients. In a six-month placebo-controlled crossover trial in 35 patients of a professionally applied calcium phosphate paste, the water placebo alone cut air-blast pain by 20% immediately and 36% at six months²⁰. That was an in-office treatment rather than a toothpaste, so the figure is not a toothpaste result; it is the size of the response a new tube has to clear before anything can be credited to its actives²⁰.

Then the two limits no formula removes. Severe pain, pain in a single tooth, pain that arrived suddenly, or sensitivity lasting more than a few weeks can mean decay, a cracked tooth, gum disease or infection, and the Oral Health Foundation sends each of those to a dentist²²; the NHS says toothache lasting more than two days needs one²³. And three actives cost more. S3 is £19.99 a tube, or £14.99 on subscription, against a chemist's own-label potassium nitrate toothpaste recorded at £1.00 for 100 ml in the same September 2026 scan; prices and formulations change, so check the pack and the site. Nothing in the trial evidence above tells you the difference is worth that multiple, and this page is not going to pretend otherwise.

So how should you judge a multi-active paste?

By asking four questions of the ingredient list, and then by running a fair test. Does the second active do a job the first one cannot, or is it a second version of the same job? Is its level declared, and on what basis — as supplied, or as active content? Does the formula keep fluoride, or ask you to give up decay protection to get the mineral? And what will you measure, and when? A comparison of the UK alternatives by active ingredient and the variant-by-variant range decoded will tell you what is in the tube you already own; the guide to switching covers what to do next.

Who a multi-active formula is for is a narrower answer than the marketing suggests: people whose current sensitivity toothpaste worked at first and then stopped, people who want hydroxyapatite without dropping fluoride, and people who would rather repair the surface than only numb the nerve. If none of those describes you, the tube you will actually keep using every morning and evening is the one that helps, whatever is in it.

Frequently asked questions

Is "triple action" just marketing for three ingredients?

It is marketing until each ingredient can be shown to do a job the others cannot, and for this formula that showing rests on mechanism, not on a measured head-to-head. Potassium acts on the nerve and seals no tubule; hydroxyapatite occludes and has no reported action on the nerve. The design that would settle it — one paste, its actives removed one at a time — has been run for other pairings, both times by the manufacturer of the pastes tested, and never for this one⁵⁸. The comparison of what occlusion and nerve-calming can each do sets the two mechanisms side by side.

Has S3's own combination been tested in a published trial?

No, not as a finished product. What exists is evidence for the ingredients separately, one laboratory study on a single tooth per formulation, and a commissioned consumer trial whose figures are what panellists said rather than what an instrument measured. The nearest published work is a manufacturer-sponsored comparison of a different mineral formulation, a three-month regimen that gave the home paste only after professional applications, and a single-arm report with no control group at all⁸¹⁷¹⁸.

Will a paste with three actives work faster than the one you are using?

Nothing measures that. In the systematic review that grouped treatments by when their effect first reached significance, only in-office treatments acted inside seven days, and potassium nitrate appears in the long-term window¹⁹. Expect the same judging period whatever the count of actives: a few weeks before anything is readable, and eight weeks before a fair verdict.

Can you get the same result by using two different toothpastes?

Nobody has tested it, so the honest answer is that it is unknown, and there is a practical reason to doubt it. Every active in this category depends on being applied continuously, and the guidance is that the effect lasts only while you keep using the paste²²; alternating tubes halves the exposure to each. It also makes the result unreadable, because you can no longer tell which paste did what — which is the argument in how long to give a new sensitivity toothpaste.

Does a higher declared percentage mean a stronger paste?

Not on the published record, and the gap is worth stating. A PubMed search in September 2026 for dose-ranging or different-concentration work on desensitising toothpastes in dentine hypersensitivity returned nothing at all. In the manufacturer-sponsored eight-week trial that carried two strengths of the same mineral, the two strengths came apart at one point of eight, on a design that was never built to answer the question⁸. A percentage on a pack is an inclusion level, and for hydroxyapatite the active content is lower than the number printed — which is why the basis matters more than the figure. The Journal's article on how sensitive toothpastes work, and why yours might not be covers what else changes the answer.